Mikrofokusy Adenokarzinom der Prostata

Prostatavergrößerung und Prostatakrebs

Ausübung von Steinen in der Prostata

Der Urologe. Das neuroendokrine Prostatakarzinom Mikrofokusy Adenokarzinom der Prostata ist eine seltene, androgenunabhängige Variante des Prostatakarzinoms, welche aktuell in ihrer Inzidenz zunimmt. Aufgrund der unterschiedlichen Tumorbiologie des NEPC im Vergleich zum konventionellen Adenokarzinom der Prostata sind die klassischen Therapieansätze des Prostatakarzinoms meist nur bedingt wirksam.

Die Literaturrecherche und Diskussion einzelner Studien befasst sich mit der oben genannten Mikrofokusy Adenokarzinom der Prostata. Aktuelle histopathologische Klassifikationen versuchen eine Unterscheidung zwischen dem NEPC und seinen Mikrofokusy Adenokarzinom der Prostata sowie dem Adenokarzinom der Prostata mit neuroendokriner Transdifferenzierung. Im Rahmen der konventionellen Chemotherapie wird nach wie vor eine platinbasierte Chemotherapie eingesetzt. Potenzielle Therapiealternativen stellen beispielsweise Angiogeneseinhibitoren dar, welche sich derzeit in der klinischen Erprobung befinden.

Neuroendocrine carcinoma of the prostate NEPC is a rare, androgen-independent variant of prostate cancer with increasing incidence of over the past few years. It commonly progresses rapidly and is associated with a poor prognosis. Based on a different tumor biology compared to adenocarcinomas of the prostate, standard therapeutic approaches for prostate cancer are ineffective. To date, no specific treatment for NEPC exists.

The purpose of this work is to provide an overview of current histopathologic characteristics, histomorphologic classifications, and current as well as future treatment options for NEPC.

The literature was reviewed and clinical trials focusing on the above mentioned objectives are discussed. Current histomorphologic classifications aim to differentiate between NEPC including its variants and neuroendocrine transdifferentiated adenocarcinoma of the prostate.

Regarding conventional chemotherapy, platinum-based schemes are still widely used. Antiangiogenetic drugs represent potential alternatives and are currently under clinical investigation. Histomorphological subtypes distinguish themselves in terms of aggressiveness, prognosis, and preferred therapeutic approaches. Treatment of NEPC differs fundamentally compared mikrofokusy Adenokarzinom der Prostata adenocarcinoma of the prostate.

There is only limited data available for the treatment of NEPC. Kretschmer, C. Wittekind, C. Stief und C. Gratzke geben an, dass kein Interessenkonflikt besteht. Dieser Beitrag beinhaltet keine Studien an Menschen oder Tieren. Skip to main content. Advertisement Hide. Das neuroendokrine Prostatakarzinom. Authors Authors and affiliations A.

Kretschmer C. Wittekind C. Stief C. Übersichten First Online: 20 November Material und Methoden Die Literaturrecherche und Diskussion einzelner Studien befasst sich mit der oben genannten Fragestellung. Ergebnisse Aktuelle histopathologische Klassifikationen versuchen eine Unterscheidung zwischen dem NEPC und seinen Subtypen sowie dem Adenokarzinom der Prostata mit neuroendokriner Transdifferenzierung.

Neuroendocrine prostate cancer. Background Neuroendocrine carcinoma of the prostate NEPC is a rare, androgen-independent variant of prostate cancer with increasing incidence of over the past few years. Objectives The purpose of this work is to provide an overview of current histopathologic characteristics, histomorphologic classifications, and current as well as future treatment options for NEPC.

Materials and methods The literature was reviewed and clinical trials focusing on the above mentioned objectives are discussed. Results Current histomorphologic classifications aim to differentiate between NEPC including its variants and neuroendocrine transdifferentiated adenocarcinoma of the prostate.

Mikrofokusy Adenokarzinom der Prostata Histomorphological subtypes distinguish themselves in terms of aggressiveness, prognosis, and preferred therapeutic approaches.

This is a preview of subscription content, log in to mikrofokusy Adenokarzinom der Prostata access. Einhaltung ethischer Richtlinien Interessenkonflikt. Attard G, Sarker D, Reid A et al Improving the outcome of patients with castration-resistant prostate cancer through rational drug development. Pienta KJ, Bradley D Mechanisms underlying the development of androgen-independent prostate cancer.

Ann Oncol 12 Suppl 2 — Google Scholar. Abrahamsson PA Neuroendocrine cells in tumour growth of the prostate. Aprikian AG, Cordon-Cardo C et al Characterization of neuroendocrine mikrofokusy Adenokarzinom der Prostata in human benign prostate and prostatic adenocarcinoma. Beltran H, Rickman DS, Park K et al Molecular characterization of neuroendocrine prostate cancer and identification of new mikrofokusy Adenokarzinom der Prostata targets.

A morphologic and immunohistochemical study of 95 cases. Santoni M, Conti A, Burattini L et al Neuroendocrine differentiation in prostate cancer: novel morphological insights and future therapeutic perspectives. Berruti A, Bollito E, Cracco CM et al The prognostic role of immunohistochemical chromogranin a expression in prostate cancer patients is significantly modified by androgen-deprivation therapy.

Prostate 70 7 — PubMed Google Scholar. Urol Oncol 33 6 Marcus DM, Goodman M, Jani AB et al A comprehensive review of incidence and survival in patients with rare histological variants of prostate cancer in the United States from to Mazzucchelli R, Morichetti D, Lopez-Beltran A et al Mikrofokusy Adenokarzinom der Prostata tumours of the urinary system and male genital organs: clinical significance. Deorah S, Rao MB, Raman R et al Survival of patients with small cell carcinoma of the prostate during — a population-based study.

Evans AJ, Humphrey PA, Belani J et al Large mikrofokusy Adenokarzinom der Prostata neuroendocrine carcinoma of prostate: a clinicopathologic summary of 7 cases of a rare manifestation of advanced prostate cancer.

Hirano D, Okada Y, Minei S mikrofokusy Adenokarzinom der Prostata al Neuroendocrine differentiation in hormone refractory prostate cancer following androgen deprivation therapy. Berruti A, Tucci M, Mosca A et al Chromogranin A expression in patients with hormone naive prostate cancer predicts the development of hormone refractory disease. Culine S, El Demery M, Lamy PJ et al Docetaxel and cisplatin in patients with metastatic androgen independent prostate cancer and circulating neuroendocrine markers.

Papandreou CN, Usmani B, Geng Y et al Results of a phase II study with doxorubicin, etoposide, and cisplatin in patients with fully characterized small-cell carcinoma of the prostate. Mazzucchelli R, Montironi R, Santinelli A et al Vascular endothelial growth factor expression and capillary architecture in high-grade PIN and prostate cancer in untreated and androgen-ablated patients.

Carducci MA, Saad F, Abrahamsson PA et al A phase 3 randomized controlled trial of the efficacy and safety of atrasentan in men with metastatic hormone-refractory prostate cancer. Kretschmer 1 Email author C. Wittekind 2 C.

Stief 1 C. Gratzke 1 1. Personalised recommendations. Cite article How to cite? ENW EndNote. Buy options.